The FDA has approved Dupixent (dupilumab) as an add-on therapy for adults with poorly controlled COPD, especially those with ...

injection site rash and injection site dermatitis were reported in the COPD trials. Adverse events more commonly observed with Dupixent (≥5%) compared to placebo in either COPD trial were back ...

Global healthcare company Sanofi and Regeneron Pharmaceuticals today announced that the US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) injection to patients suffering from ...

12, 2024 /CNW/ - Health Canada has issued a Notice of Compliance (NOC) for DUPIXENT ® (dupilumab injection) for the treatment of patients aged 1 year and older, weighing at least 15 kg, with ...

The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) injections as an add-on therapy for certain adults with poorly controlled chronic obstructive pulmonary disease (COPD).

injection site pain, and headache. EoE is a chronic, progressive disease that can severely impact a child's ability to eat and thrive, with symptoms often mistaken for other conditions. Dupixent ...

Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved ...

and injection site dermatitis were reported in the COPD studies. Adverse events more commonly observed with Dupixent (≥5%) compared to placebo in either COPD study were back pain, COVID-19 ...